IMMP - Immutep stock falls 9% amid interim data from phase 2 trial in lung cancer

Immutep (IMMP -8.8%) reported new interim data from Part B of its phase 2 trial of eftilagimod alpha (efti) in combination with Merck's Keytruda (pembrolizumab) as 2nd line therapy for patients with non-small cell lung cancer (NSCLC). The mid-stage study, called TACTI-002, is evaluating the drug combination in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line. Part A includes first line patients with NSCLC; Part B - second line patients with NSCLC, PD-X refractory; and Part C is in second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naïve. The company said that in Part B, the drug combination was seen to be safe and well tolerated, and shows encouraging signs of antitumor activity. The company added that overall response rate of 6% (2/36) and disease control rate of 36% (13/36) was seen in the intent to treat population; both

For further details see:

Immutep stock falls 9% amid interim data from phase 2 trial in lung cancer